Project Grant R01AI197937
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
- Federal Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 21, 2025, with a completion date of June 30, 2027. This award supports the development of new tools to facilitate drug discovery targeting pathogen proteasomes, which represent an emerging therapeutic target for treating parasitic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded UC San Diego a $2.91 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 25, 2025, with a completion date of August 31, 2029. The CHROME (Continuum of HIV Response Through Observational Molecular Epidemiology) project will conduct a retrospective study evaluating the effectiveness of public health activities implemented in New York...
- Federal Grant Award Summary The University of California, San Diego received a $121,182 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 5, 2025, with completion targeted for February 3, 2028. This research project investigates the roles of vaccine formulations on germinal center (GC) dynamics to advance human immunodeficiency virus (HIV) vaccine development. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $515,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Salk Institute for Biological Studies on February 10, 2026, with a completion date of January 31, 2028. The award funds fundamental research into the molecular pathways underlying drug resistance in HIV-1 integrase, specifically examining how the virus evolves complex combinations...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded UC San Diego a $812,427 Project Grant effective August 1, 2025, through July 31, 2030, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an HIV Molecular Epidemiology Dashboard for Florida. The primary deliverable is an interactive online monitoring tool that integrates de-identified and aggregated HIV sequence data with publicly available national HIV...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $3,082,513 to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 18, 2025, for a four-year project period extending through June 30, 2029. The award supports research focused on optimizing lipid prodrug delivery formulations of remdesivir nucleoside monophosphate (RVN-MP) and related broad-spectrum nucleoside antivirals to...
- Federal Project Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 8, 2025, through June 30, 2027. The award supports basic immunological research focused on understanding the mechanisms that regulate immunoglobulin gene rearrangement, specifically investigating how enhancers and epigenetic...
- Federal Project Grant Award Summary The University of California, San Diego received a $449,578 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026 through January 31, 2031. This award supports investigator-initiated biomedical research focused on understanding the molecular mechanisms of lytic polysaccharide monooxygenases (LPMOs) in bacterial pathogenesis and...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,500 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with a completion date of June 30, 2027. This award funds investigator-initiated biomedical research examining the sequence-specific determinants and impacts of NS2 (nonstructural protein 2) interactions with the Influenza A Virus...
Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded UC San Diego a $718,637 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 24, 2026, with completion targeted for January 31, 2031. The research project focuses on developing camptothecin analogs as "block and lock" therapeutic agents to suppress HIV (Human Immunodeficiency Virus) expression in people with HIV on antiretroviral therapy. The deliverables encompass basic research activities including mechanistic studies of how topotecan and related compounds inhibit HIV gene expression through epigenetic modifications, screening and validation of new camptothecin analog compounds for HIV suppression efficacy and cytotoxicity profiles, and ex vivo testing using clinical samples from people with HIV to validate therapeutic durability and longevity of compound-induced HIV silencing. The research aims to advance understanding of how camptothecin analogs function as HIV suppressors independent of their topoisomerase I activity, identify lead compound candidates with optimal therapeutic potential and minimal off-target effects, and establish proof-of-concept for reducing chronic inflammation and immune activation associated with residual viral transcription in treated HIV patients. The project will be conducted at UC San Diego's La Jolla campus and represents competitive research support emphasizing scientific merit and relevance to infectious disease public health priorities consistent with NIAID's mission to support innovative biomedical investigations advancing infectious disease treatment and management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $718.6k | 2/23/26 |